category,datetime,headline,id,image,related,source,summary,url
company,1769122805,Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider,138220314,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,"Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $467.35, signifying a +1.35% move from its prior day's close.",https://finnhub.io/api/news?id=e8fa5347af1dbcafb501b9d51f255d48b6e0d3d9f97c0f2e3728d766c6fcbf00
company,1769099820,Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day,138236060,,VRTX,MarketWatch,Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day,https://finnhub.io/api/news?id=861c2a8f5242c0d8051ba03ca7f60c2ff5d184238cce0109469ed3c4c0647cd3
company,1769098677,"Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says",138205927,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,Vertex Pharmaceuticals' (VRTX) near-term data cementing the bright prospects of investigational drug,https://finnhub.io/api/news?id=0be902895ec6a824908ac05a6ee3d810b8dc29f5833167276cc4345d172d1f0a
company,1769087182,"Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil",138226477,https://image.cnbcfm.com/api/v1/image/108255893-17691050101769105008-43630729936-1080pnbcnews.jpg?v=1769105010&w=1920&h=1080,VRTX,CNBC,The Investment Committee give you their top stocks to watch for the second half.,https://finnhub.io/api/news?id=99b6291d4ff23d4b76ee64a1c8138577acac2c46e98fa81239ad6a97feeb24b2
company,1769052944,Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX),138213381,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,"As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.",https://finnhub.io/api/news?id=f36d8bb8b2b0ebf32e48aece94196c9b9783b83f45e3a9412bd2eb4ed1c74e39
company,1769041528,Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)?,138200232,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,"In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, both citing confidence in the company’s core cystic fibrosis business and upcoming clinical data readouts in 2026–2027. This cluster of positive analyst views has sharpened investor focus on how Vertex’s cystic fibrosis franchise underpins its broader pipeline ambitions and risk profile. We’ll now look at how this wave of bullish analyst commentary around Vertex’s cystic...",https://finnhub.io/api/news?id=b4f09f1bdb822fd5518ba812ace33c5c449241d45ff5b802041fcdc3e7d3a9f2
